Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15743820 | 0.81 | AOC3 (0.73) | AOC3KDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL3252189 | 0.81 | KDM4E (0.62) | AOC3KDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL5525965 | 0.81 | KDM4E (0.62) | AOC3KDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL3251773 | 0.81 | KDM4E (0.62) | AOC3KDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL5109281 | 0.81 | KDM4E (0.62) | AOC3KDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL3244542 | 0.81 | KDM4E (0.62) | AOC3KDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL6577786 | 0.81 | AOC3 (0.73) | AOC3KDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL1389408 | 0.79 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3ADRA2C | |
| SCHEMBL8488425 | 0.79 | GAA (0.48) | AOC3KDM4EALDH1A1UBE2NCHRM1 | |
| SCHEMBL14068829 | 0.78 | TACR1 (0.56) | AOC3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236118-A1 | Pyrrolidine derivatives and method of synthesizing these | EIZAI CO., LTD (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1413574-A1 | PYRROLIDINE DERIVATIVES AND METHOD OF SYNTHESIZING THESE | Eizai Co., Ltd. (JP) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236118-A1 | Pyrrolidine derivatives and method of synthesizing these | ADH1C, ADH5, ADH1A | AOC3 1294/4885KDM4E 1456/4885ALDH1A1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.